Standard Biotools Inc. LAB
We take great care to ensure that the data presented and summarized in this overview for STANDARD BIOTOOLS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LAB
View all-
Casdin Capital, LLC New York, NY71.3MShares$76.2 Million10.73% of portfolio
-
Viking Global Investors LP58.7MShares$62.8 Million0.35% of portfolio
-
Black Rock Inc. New York, NY21.8MShares$23.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.2MShares$18.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY16.9MShares$18 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny7.08MShares$7.58 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA6.98MShares$7.46 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.6.62MShares$7.08 Million0.13% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.6.62MShares$7.08 Million0.01% of portfolio
-
Tikvah Management LLC Charlotte, NC6.55MShares$7.01 Million3.33% of portfolio
Latest Institutional Activity in LAB
Top Purchases
Top Sells
About LAB
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Insider Transactions at LAB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 28
2025
|
Casdin Partners Master Fund, L.P. Director |
BUY
Grant, award, or other acquisition
|
Direct |
58,215
+2.03%
|
$58,215
$1.06 P/Share
|
Feb 28
2025
|
Casdin Partners Master Fund, L.P. Director |
SELL
Other acquisition or disposition
|
Indirect |
545,000
-100.0%
|
$545,000
$1.06 P/Share
|
Feb 28
2025
|
Casdin Partners Master Fund, L.P. Director |
BUY
Other acquisition or disposition
|
Indirect |
545,000
+0.91%
|
$545,000
$1.06 P/Share
|
Feb 28
2025
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
4,820,959
+7.57%
|
$4,820,959
$1.06 P/Share
|
Feb 28
2025
|
Troy Cox |
BUY
Grant, award, or other acquisition
|
Direct |
62,910
+21.87%
|
$62,910
$1.06 P/Share
|
Feb 28
2025
|
Thomas D. Carey |
BUY
Grant, award, or other acquisition
|
Direct |
56,338
+36.16%
|
$56,338
$1.06 P/Share
|
Feb 20
2025
|
Michael Egholm President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
31,031
-2.1%
|
$31,031
$1.39 P/Share
|
Nov 20
2024
|
Michael Egholm President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
28,795
-1.92%
|
$28,795
$1.51 P/Share
|
Aug 27
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
250,000
+0.46%
|
$500,000
$2.19 P/Share
|
Aug 26
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
150,000
+0.28%
|
$300,000
$2.15 P/Share
|
Aug 23
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
292,100
+0.54%
|
$584,200
$2.13 P/Share
|
Aug 22
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
307,900
+0.57%
|
$307,900
$1.96 P/Share
|
Aug 21
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+0.93%
|
$500,000
$1.9 P/Share
|
Aug 20
2024
|
Jeffrey G. Black SVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,690
-1.56%
|
$6,690
$1.91 P/Share
|
Aug 20
2024
|
Michael Egholm President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
29,093
-1.9%
|
$29,093
$1.91 P/Share
|
Aug 20
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+0.94%
|
$500,000
$1.87 P/Share
|
Aug 19
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
250,000
+0.48%
|
$250,000
$1.85 P/Share
|
Aug 15
2024
|
Jeffrey G. Black SVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,695
-1.08%
|
$4,695
$1.55 P/Share
|
Aug 15
2024
|
Jeffrey G. Black SVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,157
+2.95%
|
-
|
Aug 14
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
1,200,000
+2.27%
|
$1,200,000
$1.59 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 48.8M shares |
---|---|
Other acquisition or disposition | 1.75M shares |
Open market or private purchase | 14.2M shares |
Exercise of conversion of derivative security | 332K shares |
Other acquisition or disposition | 1.75M shares |
---|---|
Payment of exercise price or tax liability | 222K shares |